Repligen SEC Filings

Type
Report
Date
SCHEDULE 13GSCHEDULE 13G-Formular2/5/2026
4Insidertransaktion1/12/2026
33-Formular1/12/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/6/2026
4Insidertransaktion12/18/2025
4Insidertransaktion12/17/2025
144144-Formular12/17/2025
4Insidertransaktion12/8/2025
4Insidertransaktion11/26/2025
144144-Formular11/25/2025
4Insidertransaktion11/19/2025
144144-Formular11/18/2025
4Insidertransaktion11/14/2025
4Insidertransaktion11/13/2025
144144-Formular11/13/2025
144144-Formular11/12/2025
10-QQuartalsbericht11/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/28/2025
4Insidertransaktion10/6/2025
4Insidertransaktion9/26/2025
4Insidertransaktion9/11/2025
144144-Formular9/10/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular9/8/2025
4Insidertransaktion9/4/2025
4Insidertransaktion9/4/2025
33-Formular9/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/2/2025
4Insidertransaktion8/12/2025
10-QQuartalsbericht8/7/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/29/2025
4Insidertransaktion5/21/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/19/2025
4Insidertransaktion5/16/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/15/2025
144144-Formular5/15/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/29/2025
10-QQuartalsbericht4/29/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/24/2025
ARSARS-Formular4/4/2025
DEFA14ADEFA14A-Formular4/4/2025
DEF 14ADEF 14A-Formular4/4/2025
4Insidertransaktion4/2/2025
4Insidertransaktion3/20/2025
4Insidertransaktion3/19/2025
4Insidertransaktion3/18/2025
PRE 14APRE 14A-Formular3/17/2025
144144-Formular3/17/2025
10-KJahresbericht3/14/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
4Insidertransaktion3/4/2025
NT 10-KNT 10-K-Formular3/3/2025
4Insidertransaktion2/28/2025
4Insidertransaktion2/28/2025
4Insidertransaktion2/28/2025
4Insidertransaktion2/28/2025
4Insidertransaktion2/28/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/20/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/13/2025
4Insidertransaktion12/5/2024
4Insidertransaktion11/22/2024
144144-Formular11/21/2024
4Insidertransaktion11/21/2024
4Insidertransaktion11/21/2024
4Insidertransaktion11/20/2024
10-Q/A10-Q/A-Formular11/18/2024
10-Q/A10-Q/A-Formular11/18/2024
10-Q/A10-Q/A-Formular11/18/2024
10-QQuartalsbericht11/18/2024
10-Q/A10-Q/A-Formular11/18/2024
10-K/A10-K/A-Formular11/18/2024
10-Q/A10-Q/A-Formular11/18/2024
SC 13G/ABeneficial ownership report11/14/2024
NT 10-QNT 10-Q-Formular11/12/2024
SC 13G/ABeneficial ownership report11/12/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/12/2024
SC 13G/ABeneficial ownership report10/23/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/18/2024
4Insidertransaktion9/12/2024
SC 13G/ABeneficial ownership report9/10/2024
144144-Formular9/10/2024
4Insidertransaktion9/4/2024
4Insidertransaktion9/4/2024
4/A4/A-Formular8/19/2024
4Insidertransaktion8/5/2024
144144-Formular8/2/2024
4Insidertransaktion8/1/2024
4Insidertransaktion8/1/2024

Repligen Documents 2026

This page contains all official documents and SEC filings for Repligen stock (RGEN, ISIN: US7599161095). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Repligen's regulatory filings.

Repligen Stock analysis

Repligen Repligen Corp is an American company that was founded in 1981 and is headquartered in Waltham, Massachusetts. The company is a leading provider of products for the biopharmaceutical industry. It offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The history of Repligen Corp begins in the 1980s when the company was originally founded to produce human proteins for medical purposes. Over the years, the company expanded its business and focused on the production of purification solutions for the biopharmaceutical industry. Today, Repligen is an established company in this field and serves customers around the world. Business model: Repligen Corp is a leading provider of products and services for the biopharmaceutical industry. The company focuses on the development and manufacturing of products for the purification of proteins and antibodies. These products are used by biotech and pharmaceutical customers to improve the effectiveness and safety of their products in the clinical development process. Repligen Corp is generally able to achieve good prices for its products as they are high-quality products for a high-priced industry. The company is also interested in introducing new products to the market and expanding its customer base. Various divisions: Repligen Corp offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The company is divided into various divisions, including: 1. Chromaflow: Repligen's Chromaflow products offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. These products enable customers to test and develop their products faster and more effectively. 2. Protein A Adsorbent Resin: Repligen Corp offers a Protein A Adsorbent Resin used in biotherapy. It allows for highly efficient purification of therapeutics produced using Protein A. 3. Alternating Tangential Flow (ATF) Systems: Repligen's ATF system enables continuous cell culture of proteins and antibodies. This facilitates the production of biopharmaceutical products and shortens development time. 4. Process Analytical Technology (PAT): Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. It improves process control and reduces the risk of errors and failures. 5. Filtration products: Repligen's filtration products include disposable filters and microfiltration membranes. These products are used by customers in the biopharmaceutical industry for the purification of biological products. Products: Repligen Corp offers a wide range of innovative products and services to support the development of biological drugs. Here are some of the products offered by Repligen Corp: 1. Protein A Adsorbent Resin: This product is used in biotherapy and the biopharmaceutical industry to enable highly efficient purification of therapeutics produced using Protein A. 2. Alternating Tangential Flow (ATF) Systems: This system enables continuous cell culture of proteins and antibodies. It facilitates the production of biopharmaceutical products and shortens development time. 3. Chromaflow products: They offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. 4. PAT systems: Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. 5. Filtration products: Repligen's filtration products include disposable filters and membranes. These products are used by customers in the biopharmaceutical industry to purify biological products. In summary, Repligen Corp is an established company that focuses on the development and production of products and services for the biopharmaceutical industry. The company offers a wide range of innovative products that contribute to the acceleration and improvement of the development of biological drugs. With its long history and established reputation as a leading provider, Repligen Corp is a significant player in the biopharmaceutical industry.